BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34062049)

  • 1. miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC.
    Citron F; Segatto I; Musco L; Pellarin I; Rampioni Vinciguerra GL; Franchin G; Fanetti G; Miccichè F; Giacomarra V; Lupato V; Favero A; Concina I; Srinivasan S; Avanzo M; Castiglioni I; Barzan L; Sulfaro S; Petrone G; Viale A; Draetta GF; Vecchione A; Belletti B; Baldassarre G
    EMBO Mol Med; 2021 Jul; 13(7):e12872. PubMed ID: 34062049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
    Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
    Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
    Leblanc O; Vacher S; Lecerf C; Jeannot E; Klijanienko J; Berger F; Hoffmann C; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Bieche I; Le Tourneau C; Kamal M
    Cancer Biol Med; 2020 Feb; 17(1):208-217. PubMed ID: 32296588
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer.
    Nair S; Trummell HQ; Rajbhandari R; Thudi NK; Nozell SE; Warram JM; Willey CD; Yang ES; Placzek WJ; Bonner JA; Bredel M
    PLoS One; 2020; 15(2):e0229077. PubMed ID: 32069320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
    Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
    Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Consequences of extracellular alterations of EGFR on cetuximab therapy in HNSCC].
    Cserepes M; Nelhűbel GA; Meilinger-Dobra M; Surguta SE; Rásó E; Ladányi A; Kenessey I; Szöőr Á; Vereb G; Remenár É; Tóvári J
    Magy Onkol; 2021 Jun; 65(2):188-195. PubMed ID: 34081766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
    Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
    Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
    [No Abstract]   [Full Text] [Related]  

  • 8. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.
    Hatakeyama H; Cheng H; Wirth P; Counsell A; Marcrom SR; Wood CB; Pohlmann PR; Gilbert J; Murphy B; Yarbrough WG; Wheeler DL; Harari PM; Guo Y; Shyr Y; Slebos RJ; Chung CH
    PLoS One; 2010 Sep; 5(9):e12702. PubMed ID: 20856931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
    Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
    Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response.
    Korpela SP; Hinz TK; Oweida A; Kim J; Calhoun J; Ferris R; Nemenoff RA; Karam SD; Clambey ET; Heasley LE
    J Transl Med; 2021 Jan; 19(1):43. PubMed ID: 33485341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells.
    Schmitt NC; Trivedi S; Ferris RL
    Mol Cancer Ther; 2015 Sep; 14(9):2103-11. PubMed ID: 26141950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
    J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
    Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
    J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling.
    Wu Q; Zhao Y; Wang P
    Biomed Pharmacother; 2018 Mar; 99():278-285. PubMed ID: 29353201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
    Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
    J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC.
    Rong C; Muller MF; Xiang F; Jensen A; Weichert W; Major G; Plinkert PK; Hess J; Affolter A
    Br J Cancer; 2020 Jul; 123(2):288-297. PubMed ID: 32424150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K
    Braig F; Kriegs M; Voigtlaender M; Habel B; Grob T; Biskup K; Blanchard V; Sack M; Thalhammer A; Ben Batalla I; Braren I; Laban S; Danielczyk A; Goletz S; Jakubowicz E; Märkl B; Trepel M; Knecht R; Riecken K; Fehse B; Loges S; Bokemeyer C; Binder M
    Cancer Res; 2017 Mar; 77(5):1188-1199. PubMed ID: 28031227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.
    Leonard B; Brand TM; O'Keefe RA; Lee ED; Zeng Y; Kemmer JD; Li H; Grandis JR; Bhola NE
    Cancer Res; 2018 Aug; 78(15):4331-4343. PubMed ID: 29792310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
    Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. lncRNA PVT1 promotes cetuximab resistance of head and neck squamous cell carcinoma cells by inhibiting miR-124-3p.
    Yang S; Yuan ZJ; Zhu YH; Chen X; Wang W
    Head Neck; 2021 Sep; 43(9):2712-2723. PubMed ID: 34033197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.